AP Biosciences (ROCO:6945) 3-Year RORE % : 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6945 AP Biosciences Inc ROCO:6945
14 GF Score
Price NT$95.80
! 1 Warning Sign
View Full Analysis

What is AP Biosciences 3-Year RORE %?

AP Biosciences ROCO:6945 -1.14% 14 3-Year RORE % is 0.00 as of Dec. 2025. GuruFocus rates ROCO:6945 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,291 Biotechnology companies, AP Biosciences ranks worse than 77459.26% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. AP Biosciences does not have enough data to calculate 3-Year RORE %.


AP Biosciences  (ROCO:6945) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


AP Biosciences 3-Year RORE % Related Terms


AP Biosciences 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for AP Biosciences's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AP Biosciences 3-Year RORE % Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.83 0.00

AP Biosciences Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.83 3.39 0.00 0.00

ROCO:6945 vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, AP Biosciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AP Biosciences 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AP Biosciences's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where AP Biosciences's 3-Year RORE % falls into.


ROCO:6945
14GF Score
AP Biosciences Inc ROCO:6945
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AP Biosciences 3-Year RORE % Calculation

AP Biosciences's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 0.00 mean?
AP Biosciences (ROCO:6945) has a 3-Year RORE % of 0.00 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on AP Biosciences and its competitors. According to the industry distribution chart, AP Biosciences ranks #999999 out of 1291 companies in the Biotechnology industry.
Is AP Biosciences' 3-Year RORE % too high?
AP Biosciences' current 3-Year RORE % is 0.00. Based on the distribution chart, AP Biosciences ranks #999999 out of 1291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AP Biosciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AP Biosciences' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AP Biosciences ranks #999999 out of 1291 companies for 3-Year RORE %. This places AP Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on AP Biosciences and its competitors. AP Biosciences's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AP Biosciences stock overvalued right now?
AP Biosciences (ROCO:6945) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. AP Biosciences' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For AP Biosciences (ROCO:6945), the current 3-Year RORE % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AP Biosciences Business Description

Address No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.
14GF Score

Get the complete analysis for ROCO:6945

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$95.80
Price